{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","upperLimit":"17.3","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Complete response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Partial response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"CR requires all of the following:\n\n* Absence of the original monoclonal paraprotein in serum and urine by immunofixation, maintained for a minimum of 6 weeks. The presence of oligoclonal bands consistent with oligoclonal immune response reconstitution does not exclude CR.\n* \\< 5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy, if biopsy is performed. If absence of monoclonal protein is sustained for 6 weeks it is not necessary to repeat the bone marrow.\n* No increase in the size or number of lytic bone lesions (development of a compression fracture does not exclude response).\n* Disappearance of soft tissue plasmacytoma\n\nPR requires all of the following:\n\n* 50% reduction in the level of the serum monoclonal paraprotein maintained for a minimum of 6 weeks.\n\n  -Reduction in 24 hr urinary light chain excretion by either \\> 90% or to \\< 200 mg, maintained for a minimum of 6 weeks.\n* 50% reduction in the size of soft tissue plas","groups":[{"description":"Dasatinib will be administered continuously at an oral dose of 70 mg BID on Days 1-28 of each 28 day cycle.","id":"OG000","title":"Dasatinib 70 mg BID"},{"description":"In patients with stable disease after 8 weeks on therapy the dasatinib will be increased to 100 mg BID on Days 1-28 on each 28 day cycle.","id":"OG001","title":"Dasatinib 100 mg BID"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Completion of treatment (median duration of therapy was 51 days)","title":"Response Rate [Complete Response (CR) and Partial Response (PR)]","type":"PRIMARY","unitOfMeasure":"participants"}